Emergent BioSolutions Completes Sale of Baltimore-Camden Manufacturing Facility to Bora Pharmaceuticals

GAITHERSBURG, Md., Aug. 20, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has completed the sale of its Baltimore-Camden pharmaceutical manufacturing facility to an affiliate of Bora Pharmaceuticals Co., Ltd. (“Bora”, TWSE: 6472). Emergent received approximately $30 million at closing, which is subject to customary post-closing adjustments.

With the transaction, Bora acquired the assets, equipment and workforce of the 88,000-square-foot manufacturing facility in Baltimore-Camden.